ReviewCancers2023
A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current research trends and hotspots of boron neutron capture therapy: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Assessment of soft error risks to cardiac implantable electronic devices for boron neutron capture therapy using field-programmable gate arrays.Japanese journal of radiology · 2026Article
- Article
- Boron-10 carriers and their applications in boron neutron capture therapy.Precision radiation oncology · 2026Review
- Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Design, Synthesis, and Biological Activity of Boron-Bearing Sugar Derivatives for Boron Neutron Capture Therapy (BNCT).Molecules (Basel, Switzerland) · 2026Article
- Review
- Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model.Nature communications · 2026Article
- Bystander and abscopal effects of boron neutron capture therapy: radiobiological mechanisms and immunotherapeutic strategies.Frontiers in oncology · 2026Review
- State-of-the-art boron clusters for boron neutron-capture therapy.Theranostics · 2026Review
- Advances in Clinical Trials of Boron Neutron Capture Therapy.Research (Washington, D.C.) · 2026Review
- Targeted Nanoboron Delivery Platform for Boron Neutron Capture Therapy in Refractory Solid Tumors.International journal of nanomedicine · 2026Review
- Hypo-segmentation ofEJNMMI research · 2025Article
- Evaluating boron neutron capture therapy as a potential treatment for unresectable gastrointestinal stromal tumors.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Article
- Synthesis of New Promising BNCT Agents Based on Conjugates ofInternational journal of molecular sciences · 2024Article
- Boron neutron capture therapy of cancer: where do we stand now?Cancer communications (London, England) · 2024Article
- A method for delivering the required neutron fluence in an accelerator-based boron neutron capture therapy system employing a lithium target.Scientific reports · 2024Article
- Targeting the organelle for radiosensitization in cancer radiotherapy.Asian journal of pharmaceutical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer treatment modality that combines targeted boron agents and neutron irradiation to selectively destroy tumor cells. In mainland China, the clinical implementation of BNCT has made certain progress, primarily driven by the development of compact neutron source devices. The availability, ease of operation, and cost-effectiveness offered by these compact neutron sources make BNCT more accessible to cancer treatment centers. Two compact neutron sources, one being miniature reactor-based (IHNI-1) and the other one being accelerator-based (NeuPex), have entered the clinical research phase and are planned for medical device registration. Moreover, several accelerator-based neutron source devices employing different technical routes are currently under construction, further expanding the options for BNCT implementation. In addition, the development of compact neutron sources serves as an experimental platform for advancing the development of new boron agents. Several research teams are actively involved in the development of boron agents. Various types of third-generation boron agents have been tested and studied in vitro and in vivo. Compared to other radiotherapy therapies, BNCT in mainland China still faces specific challenges due to its limited clinical trial data and its technical support in a wide range of professional fields. To facilitate the widespread adoption of BNCT, it is crucial to establish relevant technical standards for neutron devices, boron agents, and treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.